KPMG in Precision Medicine

The foundation of Precision Medicine (PM) has evolved from the simplicity of ‘right patient, right drug, right time’ to now encompass cutting edge sequencing, diagnostic, and therapeutic technologies that are impacting clinical outcomes for patients. We help our clients solve their most complex strategic problems on a G-LOCAL level – global strategic focus and local level execution, leveraging our deep market knowledge, and powered by a proprietary database.

Defining an organizational and capabilities roadmap for future market leadership for an oncology medical affairs team in a global biopharma client

Global market assessment of the current and future Precision Medicine landscape to optimize future launch strategies for a global biopharma client

Developing the go-forward strategy for a leading diagnostics company

The Precision Medicines deal market is one of the most active and dynamic in the Life Sciences industry. Our Precision Medicines team supports clients across the deal continuum, from front-end ideation and planning, to commercial, financial and operational due diligence, and through integration and separation. Our practice has been on the buy and sell-side for deals in the Precision Medicine ecosystem for both corporate and private entities.

Assessing the commercial viability and investment thesis of an early-stage oncology diagnostics company

Identifying M&A targets for a leading diagnostics company

Assessing the commercial viability of assets across multiple indications for a royalty rights opportunity

Operating a high-performing organization in the Precision Medicine space requires enabling capabilities and functions to bridge strategy through execution, to keep pace with regulatory changes and the evolution of technology. KPMG leverages a holistic approach, helping organizations design and align operating models with business strategy, positioning the mid- and back-office functions of Precision Medicine organizations for performance transformation and commercial success.

Current state assessment and gap analysis to design an improved maarket access governance model for a global biopharma

Setting up COVID-19 testing capabilities for one of the largest reference labs in the United States

Post-merger operational enablement of a genomics diagnostic acquisition